260 related articles for article (PubMed ID: 17404085)
21. Hypermethylation of cell-free serum DNA indicates worse outcome in patients with bladder cancer.
Ellinger J; El Kassem N; Heukamp LC; Matthews S; Cubukluoz F; Kahl P; Perabo FG; Müller SC; von Ruecker A; Bastian PJ
J Urol; 2008 Jan; 179(1):346-52. PubMed ID: 18006010
[TBL] [Abstract][Full Text] [Related]
22. Neuro-fuzzy modeling: an accurate and interpretable method for predicting bladder cancer progression.
Catto JW; Abbod MF; Linkens DA; Hamdy FC
J Urol; 2006 Feb; 175(2):474-9. PubMed ID: 16406976
[TBL] [Abstract][Full Text] [Related]
23. Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients.
Friedrich MG; Weisenberger DJ; Cheng JC; Chandrasoma S; Siegmund KD; Gonzalgo ML; Toma MI; Huland H; Yoo C; Tsai YC; Nichols PW; Bochner BH; Jones PA; Liang G
Clin Cancer Res; 2004 Nov; 10(22):7457-65. PubMed ID: 15569975
[TBL] [Abstract][Full Text] [Related]
24. Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancer.
Wang Y; Yu Z; Wang T; Zhang J; Hong L; Chen L
Lung Cancer; 2007 May; 56(2):289-94. PubMed ID: 17267069
[TBL] [Abstract][Full Text] [Related]
25. Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma.
Friedrich MG; Chandrasoma S; Siegmund KD; Weisenberger DJ; Cheng JC; Toma MI; Huland H; Jones PA; Liang G
Eur J Cancer; 2005 Nov; 41(17):2769-78. PubMed ID: 16242928
[TBL] [Abstract][Full Text] [Related]
26. The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancers.
Tada Y; Wada M; Taguchi K; Mochida Y; Kinugawa N; Tsuneyoshi M; Naito S; Kuwano M
Cancer Res; 2002 Jul; 62(14):4048-53. PubMed ID: 12124340
[TBL] [Abstract][Full Text] [Related]
27. A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer.
Yu J; Zhu T; Wang Z; Zhang H; Qian Z; Xu H; Gao B; Wang W; Gu L; Meng J; Wang J; Feng X; Li Y; Yao X; Zhu J
Clin Cancer Res; 2007 Dec; 13(24):7296-304. PubMed ID: 18094410
[TBL] [Abstract][Full Text] [Related]
28. DBC2 gene is silenced by promoter methylation in bladder cancer.
Shi Y; Chen JY; Yang J; Li B; Chen ZH; Xiao CG
Urol Oncol; 2008; 26(5):465-9. PubMed ID: 18640857
[TBL] [Abstract][Full Text] [Related]
29. Carcinogen exposure and gene promoter hypermethylation in bladder cancer.
Marsit CJ; Karagas MR; Danaee H; Liu M; Andrew A; Schned A; Nelson HH; Kelsey KT
Carcinogenesis; 2006 Jan; 27(1):112-6. PubMed ID: 15987713
[TBL] [Abstract][Full Text] [Related]
30. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.
Veeck J; Noetzel E; Bektas N; Jost E; Hartmann A; Knüchel R; Dahl E
Mol Cancer; 2008 Nov; 7():83. PubMed ID: 18990230
[TBL] [Abstract][Full Text] [Related]
31. Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study.
Dyrskjøt L; Zieger K; Real FX; Malats N; Carrato A; Hurst C; Kotwal S; Knowles M; Malmström PU; de la Torre M; Wester K; Allory Y; Vordos D; Caillault A; Radvanyi F; Hein AM; Jensen JL; Jensen KM; Marcussen N; Orntoft TF
Clin Cancer Res; 2007 Jun; 13(12):3545-51. PubMed ID: 17575217
[TBL] [Abstract][Full Text] [Related]
32. Molecular alterations associated with bladder cancer initiation and progression.
Cordon-Cardo C
Scand J Urol Nephrol Suppl; 2008 Sep; (218):154-65. PubMed ID: 18815930
[TBL] [Abstract][Full Text] [Related]
33. Prognostic effect of DNA aneuploidy from bladder washings in superficial bladder cancer.
Puntoni M; Zanardi S; Branchi D; Bruno S; Curotto A; Varaldo M; Bruzzi P; Decensi A
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):979-83. PubMed ID: 17507625
[TBL] [Abstract][Full Text] [Related]
34. Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers.
Kandimalla R; van Tilborg AA; Kompier LC; Stumpel DJ; Stam RW; Bangma CH; Zwarthoff EC
Eur Urol; 2012 Jun; 61(6):1245-56. PubMed ID: 22284968
[TBL] [Abstract][Full Text] [Related]
35. Epigenetic analysis of body fluids and tumor tissues: application of a comprehensive molecular assessment for early-stage breast cancer patients.
Taback B; Giuliano AE; Lai R; Hansen N; Singer FR; Pantel K; Hoon DS
Ann N Y Acad Sci; 2006 Sep; 1075():211-21. PubMed ID: 17108214
[TBL] [Abstract][Full Text] [Related]
36. Increase sensitivity in detecting superficial, low grade bladder cancer by combination analysis of hypermethylation of E-cadherin, p16, p14, RASSF1A genes in urine.
Lin HH; Ke HL; Huang SP; Wu WJ; Chen YK; Chang LL
Urol Oncol; 2010; 28(6):597-602. PubMed ID: 19181545
[TBL] [Abstract][Full Text] [Related]
37. [Detection and significance of APC gene promoter hypermethylation in serum of breast cancer patients].
Zhang JJ; Ouyang T; Wan WH; Xu GW; Deng GR
Ai Zheng; 2007 Jan; 26(1):44-7. PubMed ID: 17222366
[TBL] [Abstract][Full Text] [Related]
38. Epigenetic biomarkers in urothelial bladder cancer.
Kim WJ; Kim YJ
Expert Rev Mol Diagn; 2009 Apr; 9(3):259-69. PubMed ID: 19379084
[TBL] [Abstract][Full Text] [Related]
39. Urothelial carcinomas arising in arsenic-contaminated areas are associated with hypermethylation of the gene promoter of the death-associated protein kinase.
Chen WT; Hung WC; Kang WY; Huang YC; Chai CY
Histopathology; 2007 Dec; 51(6):785-92. PubMed ID: 17953697
[TBL] [Abstract][Full Text] [Related]
40. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
